Revitalizing An HCP  Campaign With Shared Costs

COMBIVENT Respimat, a COPD medication, had seen declining revenue, but the onset of COVID-19 led to increased off-label prescriptions. Partnering with EVERSANA InTouch, Boehringer Ingelheim (BI) aimed to capitalize on this trend through personalized digital campaigns. This unique shared risk/success partnership aimed to measure the potential Rx lift with minimal investment over a multi-year contract. Through revamping the website, developing key HCP focused banners, and optimizing page content, BI saw a 15% lift in scripts.